- Home
- POR vs PCVX Comparison
POR vs PCVX Comparison
Compare POR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | PCVX |
|---|---|---|
| Founded | 1889 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | POR | PCVX |
|---|---|---|
| Price | $49.13 | $43.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $46.33 | ★ $101.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 10-31-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $3,511,000,000.00 | N/A |
| Revenue This Year | $5.15 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $17.64 | ★ N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $39.55 | $27.66 |
| 52 Week High | $51.14 | $93.77 |
Technical Indicators
Market Signals| Indicator | POR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 44.74 |
| Support Level | $48.14 | $43.34 |
| Resistance Level | $49.43 | $45.15 |
| Average True Range (ATR) | 0.77 | 1.94 |
| MACD | -0.13 | -0.53 |
| Stochastic Oscillator | 48.40 | 23.12 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 300 megawatts of energy storage.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.